相关实验视频
Updated: Jun 26, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
阿布罗西提尼布相关的不良事件:使用FAERS数据库的现实世界药监测研究
1Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Expert opinion on drug safety
|May 13, 2024
概括
这项研究分析了阿布罗西替尼的现实世界不良事件 (AEs),阿托皮性皮肤炎的JAK1抑制剂. 疹湿疹 (eczema herpeticum) 显示出强烈的安全信号,而其他罕见的副作用需要临床关注.
科学领域:
- 药物监督 药物监督 药物监督
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 亚托皮炎 (AD) 是一种普遍存在的慢性炎症性皮肤疾病.
- 包括abrocitinib在内的Janus激酶 (JAK) 抑制剂是适度至重度AD的有效治疗方法.
- 对abrocitinib的真实安全数据对于临床实践至关重要.
研究的目的:
- 在现实环境中评估与abrocitinib相关的不良事件 (AE).
- 用药监测方法识别和描述abrocitinib的安全信号.
主要方法:
- 使用美国食品和药物管理局的不良事件报告系统 (FAERS).
- 采用了两种已建立的药物监测方法来量化AE信号.
- 分析了1071个报告的不良事件,其中abrocitinib是首要疑似原因.
主要成果:
- 确定了abrocitinib的85个安全信号.
- 最常见的副作用是"药物无效".
- 湿疹疹表现出最强烈的安全信号;罕见的副作用如恶化的情况,和过敏性被注意到但没有被标记.
结论:
- 已识别的AE信号支持对abrocitinib的临床监测.
- 这种药监测分析有助于识别abrocitinib治疗的风险.
- 为了患者的安全,需要注意不太常见但有意义的副作用.
相关概念视频
01:19Pharmacovigilance
826
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
826
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K